The prevalence of atrial fibrillation in a geographically well-defined population in Northern Sweden: Implications for anticoagulation prophylaxis

Journal of Internal Medicine

Volumn 272, Issue 2, 2012, Pages 170-176

  Andersson, P ^a   Londahl M ^b   Abdon, N J ^a   Terent, A ^c  

^a Hudiksvall Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Atrial fibrillation; Epidemiology; Prevalence

Indexed keywords

WARFARIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; DRUG USE; EVALUATION; FEMALE; GENDER; GROUPS BY AGE; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STROKE; SWEDEN; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DELIVERY OF HEALTH CARE; DRUG MONITORING; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; STROKE; SWEDEN; WARFARIN;

EID: 84864307121     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02519.x     Document Type: Article

References (30)

1. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999; 84: 131R-8R.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
3. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. Eur Heart J 2001; 22: 693-701.
4. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-92.
5. Heeringa J. Atrial fibrillation: is the prevalence rising? Europace 2010; 12: 451-2.
6. 2) risk stratification scheme. Am Heart J 2008; 156: 57-64.
7. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
8. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
9. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
10. Hobbs FD, Fitzmaurice DA, Mant J et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005; 9: iii-iv, ix-x, 1-74.
11. Schmutz M, Beer-Borst S, Meiltz A et al. Low prevalence of atrial fibrillation in asymptomatic adults in Geneva, Switzerland. Europace 2010; 12: 475-81.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
13. 2-VASc risk stratification scores. Age Ageing 2011; 39: 533-5.
14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
15. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32: 2282-9.
16. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47: 285-9.
17. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52.
18. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-84.
19. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 1996; 131: 790-5.
20. Murphy NF, Simpson CR, Jhund PS et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 2007; 93: 606-12.
21. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
22. Dagres N, Nieuwlaat R, Vardas PE et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007; 49: 572-7.
23. Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-91.
24. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004; 93: 1422-5.
25. Lip GY. Coronary artery disease and ischemic stroke in atrial fibrillation. Chest 2007; 132: 8-10.
26. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007; 6: 981-93.
27. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
28. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
29. Kowey PR, Reiffel JA, Myerburg R et al. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). Am J Cardiol 2010; 105: 1130-4.
30. Allen Lapointe NM, Sun JL, Kaplan S, d'Almada P, Al-Khatib SM. Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. Am J Cardiol 2008; 101: 1134-41.